Promoter polymorphisms of SERPINE1 are associated with the antidepressant response to depression in Alzheimer's disease

Neuroscience Letters

Volumn 516, Issue 2, 2012, Pages 217-220

  Fang, Yu ^a   Zhang, Lu ^a   Zeng, Zhaoshu ^b   Lian, Yajun ^a   Jia, Yanjie ^a   Zhu, Hongcan ^a   Xu, Yuming ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Depression; Plasminogen activator inhibitor 1; Polymorphism; SSRIs

Indexed keywords

PAROXETINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERPINE 1; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CHINESE; DEPRESSION; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SERPINE 1 GENE; TREATMENT RESPONSE;

AGED; ALZHEIMER DISEASE; ANTIDEPRESSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DEPRESSION; DRUG RESISTANCE; FEMALE; GENOTYPE; HUMANS; MALE; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC;

EID: 84860434364     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2012.03.090     Document Type: Article

References (38)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, Text Revision 2000, American Psychiatric Association Press, Washington, DC. 4th ed.
2. Alexopoulos G.S., Abrams R.C., Young R.C., Shamoian C.A. Cornell scale for depression in dementia. Biological Psychiatry 1988, 23:271-284.
3. Avramopoulos D. Genetics of Alzheimer's disease: recent advances. Genome Medicine 2009, 1:342-347.
4. Anthony J.C., LeResche L., Niaz U., von Korff M.R., Folstein M.F. Limits of the 'Mini-Mental State' as a screening test for dementia and delirium among hospital patients. Psychological Medicine 1982, 12:397-408.
5. Anttila S., Huuhka K., Huuhka M., Rontu R., Hurme M., Leinonen E., Lehtimaki T. Interaction between 5-HT1A and BDNF genotypes increases the risk of treatment-resistant depression. Journal of Neural Transmission 2007, 114:1065-1068.
6. Borroni B., Archetti S., Costanzi C., Grassi M., Ferrari M., Radeghieri A., Caimi L., Caltagirone C., Di Luca M., Padovani A. Role of BDNF Val66Met functional polymorphism in Alzheimer's disease-related depression. Neurobiology of Aging 2009, 30:1406-1412.
7. Caraci F., Copani A., Nicoletti F., Drago F. Depression and Alzheimer's disease: neurobiological links and common pharmacological targets. European Journal of Pharmacology 2010, 626:64-71.
8. Castaneda A.E., Tuulio-Henriksson A., Marttunen M., Suvisaari J., Lonnqvist J. A review on cognitive impairments in depressive and anxiety disorders with a focus on young adults. Journal of Affective Disorders 2008, 106:1-27.
9. Chang H.S., Lee H.Y., Ham B.J., Kang R.H., Jeong Y.J., Kim H.M., Hahn H.W., Lee M.S. Plasminogen activator inhibitor 1 gene polymorphisms and mirtazapine responses in Koreans with major depression. Asia-Pacific Psychiatry 2009, 3:143-151.
10. Chi M.H., Chang H.H., Lee S.Y., Lee I.H., Gean P.W., Yang Y.K., Lu R.B., Chen P.S. Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder. Journal of Affective Disorders 2010, 126:430-435.
11. Cummings J.L., Mega M., Gray K., Rosenberg-Thompson S., Carusi D.A., Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994, 44:2308-2314.
12. Egan M.F., Kojima M., Callicott J.H., Goldberg T.E., Kolachana B.S., Bertolino A., Zaitsev E., Gold B., Goldman D., Dean M., Lu B., Weinberger D.R. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003, 112:257-269.
13. Eriksson P., Kallin B., van't Hooft F.M., Bavenholm P., Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proceedings of the National Academy of Sciences of the United States of America 1995, 92:1851-1855.
14. Eskandari F., Mistry S., Martinez P.E., Torvik S., Kotila C., Sebring N., Drinkard B.E., Levy C., Reynolds J.C., Csako G., Gold P.W., Horne M., Cizza G. Younger, premenopausal women with major depressive disorder have more abdominal fat and increased serum levels of prothrombotic factors: implications for greater cardiovascular risk. Metabolism: Clinical and Experimental 2005, 54:918-924.
15. Exley C., Korchazhkina O.V. Plasmin cleaves Abeta42 in vitro and prevents its aggregation into beta-pleated sheet structures. Neuroreport 2001, 12:2967-2970.
16. Fawcett J., Barkin R.L. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. Journal of Affective Disorders 1998, 51:267-285.
17. Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., Hall K., Hasegawa K., Hendrie H., Huang Y., Jorm A., Mathers C., Menezes P.R., Rimmer E., Scazufca M. Global prevalence of dementia: a Delphi consensus study. Lancet 2005, 366:2112-2117.
18. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960, 23:56-62.
19. Hu Y., Russek S.J. BDNF and the diseased nervous system: a delicate balance between adaptive and pathological processes of gene regulation. Journal of Neurochemistry 2008, 105:1-17.
20. Hughes C.P., Berg L., Danziger W.L., Coben L.A., Martin R.L. A new clinical scale for the staging of dementia. British Journal of Psychiatry 1982, 140:566-572.
21. Kato M., Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Molecular Psychiatry 2010, 15:473-500.
22. Lahlou-Laforet K., Alhenc-Gelas M., Pornin M., Bydlowski S., Seigneur E., Benetos A., Kierzin J.M., Scarabin P.Y., Ducimetiere P., Aiach M., Guize L., Consoli S.M. Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease. American Journal of Cardiology 2006, 97:1287-1291.
23. Lawton M.P., Brody E.M. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969, 9:179-186.
24. Lu Y., Wang M., Liu Z., Wang F., Da Y., Jia J. No association between the promoter polymorphisms of PAI-1 gene and sporadic Alzheimer's disease in Chinese Han population. Neuroscience Letters 2009, 455:97-100.
25. McGeer P.L., McGeer E.G. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Research Brain Research Reviews 1995, 21:195-218.
26. Melchor J.P., Pawlak R., Strickland S. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. Journal of Neuroscience 2003, 23:8867-8871.
27. Modrego P.J. Depression in Alzheimer's disease. Pathophysiology, diagnosis, and treatment. Journal of Alzheimer's Disease 2010, 21:1077-1087.
28. Murer M.G., Yan Q., Raisman-Vozari R. Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's disease and Parkinson's disease. Progress in Neurobiology 2001, 63:71-124.
29. Pang P.T., Teng H.K., Zaitsev E., Woo N.T., Sakata K., Zhen S., Teng K.K., Yung W.H., Hempstead B.L., Lu B. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 2004, 306:487-491.
30. Seidah N.G., Benjannet S., Pareek S., Savaria D., Hamelin J., Goulet B., Laliberte J., Lazure C., Chretien M., Murphy R.A. Cellular processing of the nerve growth factor precursor by the mammalian pro-protein convertases. Biochemical Journal 1996, 314(Pt 3):951-960.
31. Shibata N., Kawarai T., Meng Y., Lee J.H., Lee H.S., Wakutani Y., Shibata E., Pathan N., Bi A., Sato C., Sorbi S., Bruni A.C., Duara R., Mayeux R., Farrer L.A., George-Hyslop P.S., Rogaeva E. Association studies between the plasmin genes and late-onset Alzheimer's disease. Neurobiology of Aging 2007, 28:1041-1043.
32. Shin R.A., Belmonete P.L., Zandi P.P. A review of the evidence from family, twin and adoption studies for a genetic contribution to adult psychiatric disorders. International Review of Psychiatry 2004, (16):260-283.
33. Teng H.K., Teng K.K., Lee R., Wright S., Tevar S., Almeida R.D., Kermani P., Torkin R., Chen Z.Y., Lee F.S., Kraemer R.T., Nykjaer A., Hempstead B.L., Nykjaer A., Hempstead B.L. ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and sortilin. Journal of Neuroscience 2005, 25:5455-5463.
34. Tsai S.J. The possible role of tissue-type plasminogen activator and the plasminogen system in the pathogenesis of major depression. Medical Hypotheses 2006, 66:319-322.
35. Tsai S.J., Hong C.J., Liou Y.J., Yu Y.W., Chen T.J. Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response. Pharmacogenetics and Genomics 2008, 18:869-875.
36. Yesavage J.A., Brink T.L., Rose T.L., Lum O., Huang V., Adey M., Leirer V.O. Development and validation of a geriatric depression screening scale: a preliminary report. Journal of Psychiatric Research 1982, 17:37-49.
37. Yoshida K., Higuchi H., Kamata M., Takahashi H., Inoue K., Suzuki T., Itoh K., Ozaki N. The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine. Journal of Psychopharmacology 2007, 21:650-656.
38. L. Zhang, Y. Fang, Z. Zeng, Y. Lian, J. Wei, H. Zhu, Y. Jia, X. Zhao, Y. Xu, BDNF gene polymorphisms are associated with Alzheimer's disease-related depression and antidepressant response, Journal of Alzheimer's Disease, 26 (2011) 523-530.